DPEP1 and TPX2 as Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma
Posted Nov 17 2011 7:00pm
Description of Invention: Scientists at NIH have developed prognostic biomarkers and a candidate therapeutic target for pancreatic ductal adenocarcinoma (PDAC). PDAC is a devastating cancer, and patients have an average survival of six months. The 5-year survival for PDAC patients is only 6%. This high lethality in pancreatic cancer is due to the late diagnosis and lack of any effective treatment. Greater than 80% of patients are diagnosed in an advanced stage of the disease. The instant invention is a discovery of biomarkers to make prognostic conclusions about the progression of PDAC by measuring the expression of DPEP1 and TPX2. Patients with decreased DPEP1 and increased TPX2 expression have poorer outcome. Furthermore, DPEP1 and TPX2 are controlled by the MAPK pathway. A MAPK inhibitor can be used as a treatment because it can lead to increased DPEP1 and decreased TPX2 expression, which is associated with better survival.
Prognostic biomarker to identify high-risk patients
Identification of MAPK inhibitor(s) altering DPEP1 and TPX2 expression
Combination of measuring DPEP1 and TPX2 expression levels results in improved prognosis prediction
Development of expression level patterns during tumorigenesis that are representative of PDAC
Development Status: In vivo data available (human)
DPEP1 and TPX2 as Independent Predictors of Cancer-Specific Mortality in Pancreatic Ductal Adenocarcinoma, submitted April 2011.
For Licensing Information Please Contact: Uri Reichman Ph.D., M.B.A. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 26, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4616 Fax: 301-402-0220